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The effect of the enriched effector cell populations on growth and differentiation of hematopoietic progenitor cells was studied by two different methods. CD34 þ cells were mixed in different ratios with the enriched T-cell populations and cocultured with and without preincubation for 7 days in semisolid medium; next, the erythroid colonies (BFU-E and CFU-E), granulocyticmacrophage colonies (CFU-GM) and pluripotent mixed colonies (CFU-GEM) were scored. Moreover, CD34 þ cells were mixed in different ratios with irradiated enriched T-cell populations, and inhibition of proliferation of CD34 þ cells was analyzed. Also, in these experiments, no effect of the circulating clonal T-cell populations was found on the growth and differentiation of hematopoietic progenitor cells (Table 1) .
Since no specific effector function of the circulating clonally expanded CD8
þ cytotoxic effector T cells against the most obvious target cell types affected in HCL could be demonstrated, we have to conclude that the cells must be directed against still unknown targets present in HCL patients.
A potential role for PRDM12 in the pathogenesis of chronic myeloid leukaemia with derivative chromosome 9 deletion Chronic myeloid leukaemia (CML) is a clonal haematopoeic stem cell disorder associated with the BCR-ABL fusion gene, generated by the Philadelphia (Ph) translocation t(9;22)(q34;q11). Recently, it was established that deletions of over 300 kb occur on the derivative chromosome 9 [der (9) ] in approximately 15% of CML patients. 1 The deletions, detected by fluorescent in situ hybridisation (FISH) using large commercial contig probes, were associated with rapid progression to blast crisis and short survival. A recent study by Kolomietz et al 2 used quantitative PCR to demonstrate that a further subset of der (9) deletions exist beyond the resolution of large commercial FISH probes. Subsequent mapping of the microdeletions identified a minimal commonly deleted region (CDR) of 120 kb, associated with short survival. The CDR, immediately 5 0 to ABL, contained two known genes, the ribosomal RNA processing protein 4 (RRP4) and the positive regulatory (PR)-domain zinc-finger protein 12 (PRDM12). The latter gene is a member of the closely related PR-domain-containing zinc-finger family, which appear to function as negative regulators of oncogenesis and include the tumour-associated genes MDS1-EVI1, RIZ, BLIMP1, MEL1 and PFM1.
3-7 PRDM12 therefore represents an attractive candidate tumour suppressor gene within the der(9) CDR.
We report a case of CML with short survival but no overt der(9) deletion, in which FISH identified a novel cryptic insertion of chromosome 9 sequences into chromosome 7. Detailed mapping of the extent of the insertion revealed that the distal breakpoint had occurred within a 70 kb region containing the PRMD12 gene. Our findings suggest that disruption of PRMD12 may account for the observed short survival of this patient and further support a role for this gene in the pathogenesis of CML patients with der(9) deletions.
The patient, who survived for 24 months after initial diagnosis had an apparent classical Ph translocation t(9;22)(q34;q11) as the sole cytogenetic abnormality. Application of a dual-fusion BCR-ABL FISH system to the patient's bone marrow (BM) metaphase cells revealed a BCR-ABL fusion on the Ph chromosome as expected; however, the components of the second fusion were unexpectedly separated, with the red 3 0 BCR component remaining present on the der(9), while the green 5 0 ABL fragment was visible on a C-group chromosome. This chromosome was identified by reverse DAPI banding as chromosome 7. Simultaneous application of the D-FISH probe, with a whole chromosome 7 painting probe (WCP7), confirmed the presence of sequences 5 0 of the ABL gene within the structure of chromosome 7, at band q35 ( Figure 1a) . The BM metaphase cells of this patient therefore possessed a classical Ph translocation, and, in addition, appeared to carry a submicroscopic insertion of sequences from the 9q34.1 region, centromeric to the ABL breakpoint, into band q35 of chromosome 7 ( Figure 1b) .
FISH with a panel of chromosome 9 bacterial artificial chromosome (BAC) clones was performed in order to determine the boundaries of the inserted material (Figures 1c-e) . The proximal breakpoint of the insertion was narrowed down to a 100 kb region flanked by bA203J4 and bA395P17 (Figures 1c and  d) , and harbouring no known genes (http://www.ensembl.org/ Homo_sapiens/cytoview). The BAC bA57C19 was applied to locate the distal boundry of the inserted material. The region of chromosome 9 represented in this 173 kb clone begins 109 kb 5 0 of ABL exon 1 and ends approximately 64 kb into ABL intron 1. Hybridisation of bA57C19 produced an unusual result in this patient. In addition to the signal from the normal chromosome 9 homologue, three further hybridisation signals were produced, visible on chromosome 7, der(9) and the Ph chromosome (Figure 1e ). The most likely explanation for this pattern is that the distal breakpoint of the insertion occurred in close proximity to the Ph translocation breakpoint in ABL, such that the two double-stranded breaks were within the sequence covered by clone bA57C19, thus splitting the hybridisation signal into three parts. The insertion was therefore approximately 2.5 Mb in length, and had occurred near to, but not in association with the Ph rearrangement.
To further refine the location of the distal breakpoint of the insertion, PCR products were designed from within the genomic sequence of the RRP4 gene, which maps 10 kb 5 0 to ABL exon 1b. The pooled products, covering approximately 10 kb of genomic sequence, were then labelled and used as a highresolution FISH probe. Application of this probe revealed the RRP4 locus to be present on the der(9) chromosome, and thus telomeric to the segment of chromosome 9 inserted into chromosome 7 (Figure 1f ). This finding demonstrated that the distal insertion breakpoint had occurred 5 0 to the RRP4 gene, within a 70 kb region at the centromeric end of clone bA57C19 (Figure 2) . Unfortunately, there was insufficient archived material from this patient on which to define the precise genomic rearrangements. [7] der [9] ABL BCR WCP7 Chr 9 Chr 7 Chr 22 der [7] der [9] der [22] ins(9:7) t(9:22) 7 57C19 9 9
Ph der [9] der [7] der [9] der [7] der [9] der [9] 395P 17 WCP7 , mapping approximately 3 Mb centomeric to ABL, hybridises to both homologues of chromosome 9 and is therefore proximal to the inserted chromosome 9 segment. (d) BAC bA395P17 (red) hybridised to chromosome 7 (blue), and not the der(9), therefore representing a region contained within the inserted segment. (e) Hybridisation signals from BAC bA57C19 are seen on the der(9), Ph chromosome and chromosome 7 as well as on the normal chromosome 9. This indicates that the chromosome 9 insertion does not share a breakpoint with the t(9;22) but has occurred within close proximity of the ABL Ph breakpoint, thus splitting the hybridisation signal from bA57C19 into three parts. (f) A tailored FISH probe for the RRP4 gene, located 10-21 kb 5 0 of ABL, produced hybridization signals on both homologues of chromosome 9 only, indicating that this locus lies telomeric to the distal insertion breakpoint. The PCR products used to create this probe were generated using the following primers: aagatggcgatggagatgag and aactggaaaagagcctgcac (630 bp); tgtatcttcgccttgcatca and aaacctctgaagcctgcact (355 bp); tgcagaactcatccatgtgc and ctgaaatcgaacaagccaca (566 bp); tgtgtccaggtgtggaactt and tgcctgtctttcctacaagc (814 bp); tccaagcaggagttagtctgg and ctaaagcacaggccaccgta (738 bp); tgatgtgctctgggtcaaag and tgtctgcagccactccatta (920 bp); cagctccacccatctcctta and ttcggctattaccctgcaac (958 bp); tgctatgaagcatcccttcc and ggagcccattcgactgtaac (1032 bp). Following agarose gel electrophoresis, the PCR products were purified using a gel extraction kit (Qiagen, West Sussex, UK). Pooled products were labelled by nick translation using SpectrumOrange-incorporated dUTPs (Vysis).
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Figure 2
Summary of FISH mapping data. Relative location of the FISH probes used is shown in the top two columns above a representation of part of chromosome 9q34 (red). Designations A, B and C show the location of the three breakage events detected within the 9q34 region. The centromeric insertion breakpoint (a) was mapped to a region of approximately 100 kb, between clones bA203J24 and bA395P17, containing no known genes. The distal insertion breakpoint (b) was narrowed down to a 70 kb region within the sequence of clone bA57C19 containing genes FUBP3 and PRDM12. The total extent of the inserted material was therefore estimated to be approximately 2.5 Mb. The breakpoint in ABL (c) resulting in the BCR-ABL fusion was distinct from the distal insertion breakpoint since the hybridisation signal from clone bA57C19 was split into three by the rearrangement (see Figure 1c) .
The 70 kb region harbouring the distal breakpoint contains PRDM12, in addition to a second gene fuse binding protein 3 (FBP3), one of a family of three genes known to positively regulate c-MYC expression. Loss of function of FBP genes arrests cellular proliferation and extinguishes c-MYC expression, 8 therefore it is unlikely that disruption of this gene is responsible for the aggressive disease course seen in this patient. In contrast, abrogation of PRDM12 represents an attractive mechanism to explain this patient's short survival. Although little is known about the function of this particular gene, all known members of the closely related PRDM family map to chromosomal regions that commonly undergo deletions in human cancer. 5 Indeed, haploinsuffuciency has been proposed as a model to explain the more aggressive phenotype of homozygous knockouts of RIZ, the most widely studied PRDM family member. 3 In addition, structural rearrangement, mutation and/or aberrant expression of RIZ, MDS-EVI1 and MEL1 have been reported in myeloid malignancies. 4, 7, 9 PRDM family members share the feature of expressing two protein products that differ in the presence or absence of the PR domain. 5 Studies of RIZ, MDS-EVI1, MEL1 and BLIMP-1 have revealed that a variety of tumour types often overexpress the PR domain-negative product, relative to the fulllength protein. 4, 5, 7, 9 It is tempting to speculate that in our patient, the distal insertion breakpoint abrogated sequences coding for the 5 0 PR domain of PRDM1, thus causing a relative decrease in the proportion of PR-domain-positive product.
The hypothesis that disruption of PRMD12 precipitated an aggressive phenotype in this patient is in keeping with the suggestion that this gene may behave as a classical tumour suppressor in cases of CML with deletion of der (9) . 2 The PRMD12 gene warrants further attention in order to elucidate its role in the pathogenesis of CML.
TO THE EDITOR CD38 is a surface marker associated with aggressive disease course and overall shorter survival time in B-cell chronic lymphocytic leukemia (B-CLL). Several groups, including our laboratory, have investigated this marker on CLL B cells and found that greater than 30% CD38 expression within a CLL leukemic population correlates to an overall shorter time to progression and, in general, a poor clinical outcome. [1] [2] [3] [4] [5] However, another study suggests that scoring CLL B-cell CD38 expression using both percent-positive and mean fluorescence intensity (MFI) is a more accurate prognostic tool for B-CLL patients. 6 Recently, Ghia et al 7 found that even a small distinct population of CD38 pos cells, displayed as a small peak in a bimodal CD38-staining profile, was associated with progressive disease. Taken together, these findings provide support for the positive association between CD38 expression and disease progression.
We have considered that the bimodal expression of CD38 means that there are stable subclones within the leukemic CLL B-cell population. Since CD38 expression correlates with progressive disease, it is possible that the CD38 þ leukemic cell population within patients displaying bimodal levels of this marker may be more resistant to therapy. To address this possibility, we decided to follow the CD38 expression profile of leukemic cells from a patient who is currently receiving a total of six cycles of a poly-therapy protocol (PCR) that employs
